Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 3, 2016, Pages 441-448

  Rondelli, Damiano ^a,b,b   Sweiss, Karen ^a   Pickard, A Simon ^a   Peace, David ^a,b   Quigley, John G ^a,b   Khan, Irum ^a,b   Mahmud, Nadim ^a,b   Molokie, Robert E ^a,a   Levinson, Dennis J ^a   Gordeuk, Victor R ^a,a  

^a UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

ABO mismatch; Adult; Alemtuzumab; Allogeneic transplantation; Quality of life; Sickle cell disease

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; MYCOPHENOLATE MOFETIL; PENICILLIN V POTASSIUM; RAPAMYCIN; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CHIMERA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT FAILURE; HEMOGLOBIN DETERMINATION; HUMAN; LOW ENERGY RADIATION; MAJOR CLINICAL STUDY; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; QUALITY OF LIFE; RADIATION DOSE; SICKLE CELL ANEMIA; THORAX PAIN; WELLBEING; WHOLE BODY RADIATION; ALLOGRAFT; ANEMIA, SICKLE CELL; CLINICAL TRIAL; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDY; TRANSPLANTATION CONDITIONING;

ADOLESCENT; ADULT; ALLOGRAFTS; ANEMIA, SICKLE CELL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; TRANSPLANTATION CONDITIONING; WHOLE-BODY IRRADIATION;

EID: 84949256660     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.08.036     Document Type: Article

References (31)

1. 1 Platt, O.S., Brambilla, D.J., Rosse, W.F., et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330 (1994), 1639–1644.
2. 2 Kauf, T.L., Coates, T.D., Huazhi, L., et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol 84 (2009), 323–327.
3. 3 Panepinto, J.A., Torres, S., Bendo, C.B., et al. PedsQL Multidimensional Fatigue Scale in sickle cell disease: feasibility, reliability, and validity. Pediatr Blood Cancer 61 (2014), 171–177.
4. 4 Bernaudin, F., Socie, G., Kuentz, M., et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 110 (2007), 2749–2756.
5. 5 Vermylen, C., Cornu, G., Bone marrow transplantation for sickle cell disease. The European experience. Am J Pediatr Hematol Oncol 16 (1994), 18–21.
6. 6 Walters, M.C., Storb, R., Patience, M., et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 95 (2000), 1918–1924.
7. 7 Panepinto, J.A., Walters, M.C., Carreras, J., et al. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol 137 (2007), 479–485.
8. 8 van Besien, K., Bartholomew, A., Stock, W., et al. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant 26 (2000), 445–449.
9. 9 Iannone, R., Casella, J.F., Fuchs, E.J., et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 9 (2003), 519–528.
10. 10 Krishnamurti, L., Kharbanda, S., Biernacki, M.A., et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 14 (2008), 1270–1278.
11. 11 Hsieh, M.M., Fitzhugh, C.D., Weitzel, R.P., et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA 312 (2014), 48–56.
12. 12 Bolanos-Meade, J., Fuchs, E.J., Luznik, L., et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 120 (2012), 4285–4291.
13. 13 Sorror, M.L., Maris, M.B., Storb, R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005), 2912–2919.
14. 14 Ware, J.E. Jr., Sherbourne, C.D., The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992), 473–483.
15. 15 Ware, J.E., Kosinski, M., Dewey, J.E., Gandek, B., SF-36 Health Survey: Manual and Interpretation Guide. 2000, Quality Metric Inc.
16. 16 Brazier, J., Roberts, J., Deverill, M., The estimation of a preference-based measure of health from the SF-36. J Health Econ 21 (2002), 271–292.
17. 17 Middel, B., van Sonderen, E., Statistical significant change versus relevant or important change in (quasi) experimental design: some conceptual and methodological problems in estimating magnitude of intervention-related change in health services research. Int J Integr Care, 2, 2002, e15.
18. 18 Cohen, J., Statistical power analysis for the behavioral sciences (ed Second). 1988, Lawrence Erlbaum Associates, New Jersey.
19. 19 Walters, S.J., Brazier, J.E., What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes, 1, 2003, 4.
20. 20 Hsieh, M.M., Kang, E.M., Fitzhugh, C.D., et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 361 (2009), 2309–2317.
21. 21 Kuentz, M., Robin, M., Dhedin, N., et al. Is there still a place for myeloablative regimen to transplant young adults with sickle cell disease?. Blood 118 (2011), 4491–4492 author reply 4492-4493.
22. 22 Iannone, R., Luznik, L., Engstrom, L.W., et al. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia. Blood 97 (2001), 3960–3965.
23. 23 Walters, M.C., Patience, M., Leisenring, W., et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 7 (2001), 665–673.
24. 24 Villa, A., Aboalela, A., Luskin, K.A., et al. Mammalian target of rapamycin inhibitor-associated stomatitis in hematopoietic stem cell transplantation patients receiving sirolimus prophylaxis for graft-versus-host disease. Biol Blood Marrow Transplant 21 (2015), 503–508.
25. 25 Kelly, M.J., Pennarola, B.W., Rodday, A.M., et al. Health-related quality of life (HRQL) in children with sickle cell disease and thalassemia following hematopoietic stem cell transplant (HSCT). Pediatr Blood Cancer 59 (2012), 725–731.
26. 26 Bhatia, M., Kolva, E., Cimini, L., et al. Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 21 (2015), 666–672.
27. 27 Arnold, S.D., Jin, Z., Sands, S., et al. Allogeneic hematopoietic cell transplantation for children with sickle cell disease is beneficial and cost-effective: a single-center analysis. Biol Blood Marrow Transplant 21 (2015), 1258–1265.
28. 28 World Health Organization. Global distribution of haemoglobin disorders, in terms of births of affected infants per 1000 births. Available at: http://www.who.int/genomics/public/Maphaemoglobin.pdf. Accessed April 1, 2015.
29. 29 Walters, M.C., Patience, M., Leisenring, W., et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 2 (1996), 100–104.
30. 30 Justus, D., Perez-Albuerne, E., Dioguardi, J., et al. Allogeneic donor availability for hematopoietic stem cell transplantation in children with sickle cell disease. Pediatr Blood Cancer 62 (2015), 1285–1287.
31. 31 Mahmud, D., Nicolini, B., van den Dries, L., et al. Human CD4(+)CD25(+) cells in combination with CD34(+) cells and thymoglobulin to prevent anti-hematopoietic stem cell T cell alloreactivity. Biol Blood Marrow Transplant 17 (2011), 61–68.